Eris Lifesciences Delivers Solid Q2 FY27 Results Driven by Core DBF Franchise
Eris Lifesciences Ltd 路 Investor Presentation 路 26 Oct 2026, 7:25 pm
Eris Lifesciences Delivers Solid Q2 FY27 Results Driven by Core DBF Franchise Eris Lifesciences reported consolidated revenue growth of 12.6% YoY to Rs. 892 cr in Q2 FY27, with EBITDA rising 7.3% YoY to Rs. 309 cr (34.7% margin) and PAT surging 39.2% YoY to Rs. 187 cr (Adjusted PAT up 17.5% to Rs. 158 cr). Domestic Branded Formulations revenue climbed 14.1% YoY to Rs. 809 cr, driven by chronic therapies. In H1 FY27, ROCE expanded to 19% from 16% in FY26, alongside a net debt reduction of ~Rs. 111 cr.
Original exchange filing (PDF)
More announcements from Eris Lifesciences Ltd
- as attached 路 13 Nov 2026
- The Company will host "Eris Investor Meet - 2026" on November 19, 2026 路 29 Oct 2026
- as attached 路 29 Oct 2026
- as attached 路 27 Oct 2026
- as attached 路 26 Oct 2026
- as attached 路 26 Oct 2026
- Eris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 26 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 路 26 Oct 2026
